NIH | National Cancer Institute | NCI Wiki  

You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 2 Next »

Date

Attendees

Committee MemberPresentAbsent
Kuffel, Gina (NIH/NCI) [C]
X

Musk, Philip (NIH/NCI) [C]



Warren Kibbe
X
Kim, Erika (NIH/NCI) [E]


Gregory Tawa
X
William Hendriks
X
Matthew Breen
X
Roel Verhaak



Goals

  • Review, discuss, and prioritize ICDC study submission proposals

Outstanding Action items

  • Matthew & Warren to write an email request to Toby pertaining to formalization of a business plan for ICDC.
  • Musk, Philip (NIH/NCI) [C] to brush up on Nanostring documentation.

Agenda

Discussion ItemWhoNotes
Data submission request approved by Senior Advisory Committee

Kuffel, Gina (NIH/NCI) [C] 

  • "Immune Pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma" 
  • Data Submission Folder: OSA-Normal
New data submission request

Kuffel, Gina (NIH/NCI) [C] 

PRECINCT Data Request Submission: Inhaled IL-15 Immunotherapy for Treatment of Lung Metastases

All

Review of other Modiano publications: Other Modiano Publication Considerations.xlsx

Kuffel, Gina (NIH/NCI) [C]

Study Updates

Musk, Philip (NIH/NCI) [C]

  • TCL01
    • Study identifier changed to TCL01 (Tumor Cell Line)
    • In the hands of the testing team
    • Pending release record available on production
    • 6 study files being assembled
  • PRECINCT
    • Program now available on lower tier (dev environment)
    • Study record is in place
  • PANCAN01 (15 TB Re-analysis)
    • Data is already in a ICDC S3 bucket
    • Study onboarding on the horizon

Minutes (Not Verbatim)


Action items

  • No labels